Anna Shmagel

Anna Shmagel

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2016 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
ASAnna Shmagel
Anna Shmagel
RFRobert Foley
Robert Foley
HIHassan Ibrahim
Hassan Ibrahim
Objective: To describe the epidemiologic characteristics and associations with increased health care utilization in US adults with chronic low back pain (LBP).Methods: The National Health and Nutrition Examination Survey 2009–2010 was administered to adults ages 20–69 years (n = 5,103). Chronic LBP was defined as pain in the area between the lower posterior margin of the rib cage and the horizontal gluteal fold, with a history of pain lasting almost every day for at least 3 months. Demographic and behavioral characteristics were compared between those with chronic LBP and those without. Factors associated with ≥10 health care visits per year were evaluated in the chronic LBP subgroup (n = 700).Results: Chronic LBP associations with adjusted odds ratios (ORadj) ≥2 included age 50–69 years, less than high school education, annual household income <$20,000, income from disability, depression, sleep disturbances, and medical comorbidities. Subjects with chronic LBP were more likely to be covered by government‐sponsored insurance plans (ORadj 3.23 [95% confidence interval (95% CI) 2.19–4.75] for Medicaid and ORadj 2.25 [95% CI 1.57–3.22] for Medicare; P < 0.0001), and visited health care providers more frequently (ORadj 3.35 [95% CI 2.40–4.67] for ≥10 health care visits in the past year; P < 0.0001). In the chronic LBP subgroup, adjusted ORs ≥2 were found for associations between ≥10 visits per year and unemployment, income from disability, depression, and sleep disturbances.Conclusion: US adults with chronic LBP are socioeconomically disadvantaged, make frequent health care visits, and are often covered by government‐sponsored health insurance. The clustering of behavioral, psychosocial, and medical issues should be considered in the care of Americans with chronic LBP.

21 June 2018 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
PTPhilip J. Titcombe
Philip J. Titcombe
GWGustaf Wigerblad
Gustaf Wigerblad
NSNatalie Sippl
Natalie Sippl
NZNa Zhang
Na Zhang
ASAnna Shmagel
Anna Shmagel
DMDaniel L. Mueller
Daniel L. Mueller

30 January 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ASAnna Shmagel
Anna Shmagel
RDRyan T. Demmer
Ryan T. Demmer
DKDan Knights
Dan Knights
MBMary E. Butler
Mary E. Butler
LLLisa Langsetmo
Lisa Langsetmo
KEKristine Ensrud
Kristine Ensrud
Oral glucosamine sulfate (GS) and chondroitin sulfate (CS), while widely marketed as joint-protective supplements, have limited intestinal absorption and are predominantly utilized by gut microbiota. Hence the effects of these supplements on the gut microbiome are of great interest, and may clarify their mode of action, or explain heterogeneity in therapeutic responses. We conducted a systematic review of animal and human studies reporting the effects of GS or CS on gut microbial composition. We searched MEDLINE, EMBASE, and Scopus databases for journal articles in English from database inception until July 2018, using search terms microbiome, microflora, intestinal microbiota/flora, gut microbiota/flora and glucosamine or chondroitin. Eight original articles reported the effects of GS or CS on microbiome composition in adult humans (four articles) or animals (four articles). Studies varied significantly in design, supplementation protocols, and microbiome assessment methods. There was moderate-quality evidence for an association between CS exposure and increased abundance of genus Bacteroides in the murine and human gut, and low-quality evidence for an association between CS exposure and an increase in Desulfovibrio piger species, an increase in Bacteroidales S24-7 family, and a decrease in Lactobacillus. We discuss the possible metabolic implications of these changes for the host. For GS, evidence of effects on gut microbiome was limited to one low-quality study. This review highlights the importance of considering the potential influence of oral CS supplements on gut microbiota when evaluating their effects and safety for the host.

1 October 2018 in The Journal of Pain
Verified
Journal Article
Closed access
ASAnna Shmagel
Anna Shmagel
LNLinh Ngo
Linh Ngo
KEKristine Ensrud
Kristine Ensrud
RFRobert Foley
Robert Foley

1 May 2018 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
ASAnna Shmagel
Anna Shmagel
NON. Onizuka
N. Onizuka
LLL. Langsetmo
L. Langsetmo
TVT. Vo
T. Vo
RFR. Foley
R. Foley
PVP. Valen
P. Valen

1 September 2016 in Spine
Verified
Journal Article
Closed access
ASAnna Shmagel
Anna Shmagel
EKErin Krebs
Erin Krebs
KEKristine Ensrud
Kristine Ensrud
RFRobert Md Foley
Robert Md Foley
Study Design. A population-based cross-sectional survey. Objective. The aim of this study was to compare the prevalence of illicit drug use among US adults with and without chronic low back pain (cLBP). Summary of Background Data. Although addictive medications, such as opioids and benzodiazepines, are frequently prescribed to patients with cLBP, little is known about illicit drug use among Americans with cLBP. Methods. We used data from the back pain survey, administered to a representative sample of US adults aged 20 to 69 years (N = 5103) during the 2009 to 2010 cycle of the National Health and Nutrition Examination Survey (NHANES). Participants with pain in the area between the lower posterior margin of the ribcage and the horizontal gluteal fold for at least 3 months were classified as having cLBP (N = 700). The drug use questionnaire was self-administered in a private setting, and included data on lifetime and current use of marijuana or hashish, cocaine, heroin, and methamphetamine. Chi-square tests, one-way analysis of variance, and logistic regression, adjusted for age, gender, race, and level of education, were used for comparisons. Results. About 46.5% of US adults with cLBP used marijuana versus 42% of those without cLBP [Adjusted odds ratio (aOR) 1.36, 95% confidence interval (95% CI) 1.06–1.74]. About 22% versus 14% used cocaine (aOR 1.80, 95% CI 1.45–2.24), 9% versus 5% used methamphetamine (aOR 2.03, 95% CI 1.30–3.16), and 5% versus 2% used heroin (aOR 2.43, 95% CI 1.44–4.11). Subjects with cLBP who reported lifetime illicit drug use were more likely to have an active prescription for opioid analgesics than those without illicit drug use history: 22.5% versus 15.3%, P = 0.018. Conclusion. cLBP in community-based US adults was associated with higher odds of using marijuana, cocaine, heroin, and methamphetamine. Prescription opioid analgesic use was more common in cLBP sufferers with a history of illicit drug use. Level of Evidence: 2